VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

The poster will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025. The Trial in Progress poster includes an overview and study ...

Following the presentations, each poster will be available on the Publications page of Liquidia's website at https://liquidia.com/publications.

Altis's AI Model Outperforms RECIST 1.1 in Predicting Overall Survival These findings showcase IPRO-Δ's potential to accelerate clinical d ...

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...

Q4 2024 Earnings Call Transcript March 27, 2025 BioAtla, Inc. beats earnings expectations. Reported EPS is $-0.285, ...

These changes in lung function calculations had implications ... Therapeutic management was the focus of another AAAAI poster addressing the impact of race-based spirometry in 2076 children ...